PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/
← Fund Intelligence
DOSSIER // VERIFIED INTEL

BVF Partners

San Francisco, CABVF-PARTNERS
0
Truth Cards
0
Partners Rated
Avg Score
Get Access
Access Level
◈ Truth Cards
0 VERIFIED

No verified intel yet.
Be the first founder to leave a truth card.

Request Founder Access →
Dossier Summary

No summary available yet.

Classification
Slugbvf-partners
HQSan Francisco, CA
Stage FocusThe firm focuses exclusively on biotechnology sector inve…
Intel StatusAccepting submissions
🔥 BERNIE'S HOT TAKE

BVF is the granddaddy of biotech investing - Mark Lampert literally helped invent this category when most VCs thought biotech was too risky. They're not your typical chatty social media VCs; they do their talking with their wallets and 30+ year track record. With $6B AUM, they can write real checks but focus on small-cap biotechs where they can actually move the needle. Matthew Perry's departure to start Coastlands suggests potential succession planning issues, which is concerning given Lampert's central role. They're known for deep fundamental research and taking concentrated positions, but founders should expect rigorous due diligence - these aren't spray-and-pray investors.

KEY TAKEAWAYS
  • Best for: Small-cap biotech companies needing patient capital and deep industry expertise
  • Watch out for: Extremely rigorous due diligence process and high conviction bar
  • Known for: 30+ year track record in biotech value investing and concentrated portfolio approach
Investment Thesis

BVF Partners specializes in fundamentally-driven public biotechnology investments, focusing on concentrated, long-term investments in small-cap biotechnology companies. They look through short-term events to identify companies trading cheap relative to their potential, building a portfolio that provides compelling asymmetric risk-reward profiles with attractive returns and low probability of capital impairment.

Stage & Sector Focus

The firm focuses exclusively on biotechnology sector investments, with a primary focus on companies with market caps between $100M and $1B. They primarily invest in Series A and Series B stages, though they've participated in PIPE, Series A, B, D, and F rounds. Their approach blends public and private biotech investing.

Notable Portfolio
Mirum PharmaceuticalsCG OncologySepternaCrossbow TherapeuticsImmunic TherapeuticsRepare TherapeuticsMerida BiosciencesAntares Therapeutics
Key Partners
Mark Lampert
Founder, CEO & President

Active in biotechnology since 1984, previously VP at Oppenheimer & Co and founder of Biotechnology Royalty Corp. Harvard MBA and served on boards of numerous public and private companies. Known as an incredibly helpful person in the industry.

Matthew Perry
President & Portfolio Manager

President of BVF and portfolio manager, joined in December 1996 and has been lead investor in dozens of transactions for over twenty years. Now Managing Partner at Coastlands Capital after his tenure at BVF. Known for value-oriented approach and board experience.

Have a specific question about BVF Partners?

Ask Bernie →
INVESTOR ACCESS PERMANENTLY DENIEDBERNBOOK // DOSSIER v1